Monitor MHRA decision on Herlystic (OST-HER2) CMAA in Q4 2026 as the next major catalyst. The delay in AP due dates to Q2 2027 suggests management's confidence in near-term cash inflows from VAT/R&D credits and potential financing. The CFO's performance-based equity grants tied to capital raises and PRV sale provides a direct incentive to execute on those milestones.
Price Chart
Executive Summary
OS Therapies appointed Frank Knuettel II as CFO and Kerry Clem as CCO, replacing outgoing CFO Christopher Acevedo. The press release also disclosed receipt of over $3 million in non-dilutive VAT refunds, over $7 million in accrued R&D tax credits, and a delay in AP due dates to Q2 2027. These appointments and financial updates signal preparation for the commercial launch of lead candidate Herlystic (OST-HER2) ahead of a potential MHRA decision in Q4 2026.
Key Facts
- Frank Knuettel II appointed CFO, replacing Christopher Acevedo who remains as consultant.
- Kerry Clem appointed CCO to lead U.S., U.K., and European launch planning for Herlystic.
- Knuettel receives $300k base salary, 750k options + 250k RSUs initial grant, plus milestone-based performance grants tied to capital raises, out-licensing, PRV sale, and analyst initiation.
- Clem receives $300k base salary, 700k options + 200k RSUs initial grant.
- Company received over $3 million in non-dilutive VAT refunds to date, with additional refunds pending.
- Over $7 million in R&D Tax Credits accrued for OSTUK, earmarked for commercial manufacturing and Phase 3 development.
- Company reached agreement with largest vendors delaying majority of outstanding AP due dates delayed to Q2 2027.
- MHRA Conditional Marketing Authorization Application (CMAA) submission targeted for early Q4 2026.
- PRV sale in August 2026 for $220 million referenced as benchmark for potential future PRV sale.
Financial Impact
Over $3 million in non-dilutive VAT refunds received; over $7 million in R&D tax credits accrued; AP due dates delayed to Q2 2027. No revenue or earnings figures reported.
Risk Factors
- Regulatory approval risk for Herlystic (OST-HER2) is subject to regulatory review and conditions.
- Company is a clinical-stage company with no reported revenue; no financial data to assess.
- Potential dilution from equity awards to new executives if performance milestones are not achieved.
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-106849 |
| Document: ea0307611-8k_ostherapies.htm | 0001213900-26-106849 |
| Document: ea030761101ex10-2.htm | 0001213900-26-106849 |
| Document: ea030761101ex99-1.htm | 0001213900-26-106849 |
| Document: 0001213900-26-106849-index-headers.html | 0001213900-26-106849 |
| Document: 0001213900-26-106849-index.html | 0001213900-26-106849 |
| Document: 0001213900-26-106849.txt | 0001213900-26-106849 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $1.27 $1.26 | ▼ −0.79% | ▼ −1.12% | $1.25 (−1.57%) |
Oct 5, 2026 20d ago | 3 | $1.49 $1.55 | ▲ +4.03% | ▲ +4.27% | $1.25 (−16.11%) |
Oct 5, 2026 20d ago | 8-K | $1.49 $1.55 | ▲ +4.03% | ▲ +4.27% | $1.25 (−16.11%) |
Jul 29, 2026 12w ago | 8-K | $1.56 $1.52 | ▼ −2.56% | ▼ −3.27% | $1.25 (−19.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers